Cargando…
Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
As the world's population ages, the incidence of Parkinson's disease (PD), the second most common neurological ailment, keeps increasing. It is estimated that 1% of the global population over the age of 60 has the disease. The continuous loss of dopaminergic neurons and the concomitant bra...
Autores principales: | Alabrahim, Obaydah Abd Alkader, Azzazy, Hassan Mohamed El-Said |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724695/ https://www.ncbi.nlm.nih.gov/pubmed/36540116 http://dx.doi.org/10.1039/d2na00524g |
Ejemplares similares
-
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017) -
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016) -
Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020) -
Multi-responsive paper chemosensors based on mesoporous silica nanospheres for quantitative sensing of heavy metals in water
por: El-Sewify, Islam M., et al.
Publicado: (2023) -
A bacterial cellulose-based LiSrVO(4):Eu(3+) nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease
por: Mahdavi, Mohammad, et al.
Publicado: (2023)